Warfarin anticoagulation and survival: A cohort analysis from the Studies of Left Ventricular Dysfunction

Journal of the American College of Cardiology

Volumn 31, Issue 4, 1998, Pages 749-753

  Al Khadra, Ayman S ^a   Salem, Deeb N ^a   Rand, William M ^a   Udelson, James E ^a   Smith, John J ^a   Konstam, Marvin A ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FUNCTIONAL ASSESSMENT; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME;

ANGINA, UNSTABLE; ANTICOAGULANTS; CARDIAC OUTPUT, LOW; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COHORT STUDIES; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT; WARFARIN;

EID: 0032521255     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00006-0     Document Type: Article

References (15)

1. 1. Sbarouni E, Bradshaw A, Andreotti F, Tuddenham E, Oakley CM, Cleland JG. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J 1994;127:607-12.
2. 2. Jafri SM, Ozawa T, Mammen E, Levine TB, Johnson C, Goldstein S. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur Heart J 1993;14:205-12.
3. 3. Yamamoto K, Ikeda U, Furuhashi K, Irokawa M, Nakayama TM, Shimada K. The coagulation system is activated in idiopathic cardiomyopathy. J Am Coll Cardiol 1995;25:1634-40.
4. 4. Fuster V, Gersh B, Giuliani E, et al. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981;47:525-30.
5. 5. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn J, for the V-HeFT Cooperative Studies Group. Incidence of thromboembolic events in congestive heart failure. Circulation 1993;87 Suppl VI:VI-94-101.
6. 6. Ciaccherie M, Castelli Q, Cecchi F, et al. Lack of correlation between intracavitary thrombosis detected by cross-sectional echocardiography and systemic emboli in patients with dilated cardiomyopathy. Br Heart J 1989; 62:26-9.
7. 7. Sherman D, Dyken M, Fisher M, et al. Antithrombotic therapy for cerebrovascular disorders. Chest 1989;95:1405-1555.
8. 8. Kyrle P, Korninger C, Gossinger H, et al. Prevention of arterial and pulmonary embolism by oral anticoagulants in patients with dilated cardiomyopathy. Thromb Haemost 1985;54:521-3.
9. 9. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323:147-52.
10. 10. Veterans Administration Cooperative Study. Anticoagulants in acute myocardial infarction: results of a cooperative clinical trial. JAMA 1973;225: 724-9.
11. 11. Report of the Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980;2:989-94.
12. 12. ASPECT Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;343:499-503.
13. 13. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
14. 14. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
15. 15. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57.